Reaction
Gastroenteritis Escherichia Coli reporting signals
As of the last recalculation, Gastroenteritis Escherichia Coli appears in 529 FAERS reports alongside 11 co-occurring drug terms. The strongest observed disproportionality signal is BASILIXIMAB (PRR 58.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Basiliximab | 17 | 58.7 | 58.8 |
| Valganciclovir Hydrochloride Powder, | 15 | 49.8 | 49.8 |
| Anti-Thymocyte Globulin (Rabbit) | 9 | 44.6 | 44.7 |
| Valganciclovir | 17 | 36.6 | 36.7 |
| Valganciclovir Hydrochloride | 17 | 36.6 | 36.7 |
| Mycophenilic Acid | 15 | 29.3 | 29.3 |
| Thiotepa | 6 | 25.0 | 25.0 |
| Irinotecan Hydrochloride | 7 | 21.7 | 21.7 |
| Vedolizumab | 36 | 17.6 | 17.6 |
| Pegaspargase | 5 | 16.2 | 16.2 |
| Ozanimod Hydrochloride | 3 | 14.3 | 14.3 |